Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 953-917-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
In a preliminary,Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test (OECD 422) of the source substance, at a dose of 1000 mg/kg/day, there was an increase in the number of animals giving birth to dead pups and also in the number losing more than 3 pups over Days 0-4 of lactation, compared with Controls. Therefore, for the neonatal toxicity, the Lowest Observed Adverse Effect Level (LOAEL) was 1000 mg/kg/day and the No Observed Effect Level (NOEL) was considered to be 500 mg/kg/day.From the findings on this study, the parental NOAEL was considered to be 100 mg/kg/day, however, findings at 500 and 1000 mg/kg/day were confined to salivation, and kidney findings which may be reversible and not relevant in man. The neonatal NOEL was considered to be 500 mg/kg/day.As findings in this study were considered not to be relevant in man, the parental NOAEL for man could be 1000 mg/kg/day.
In a subsequent, two generation reproductive toxicity study (OECD 416), the dietary administration of the source substance was well tolerated, and the parental and reproductive No-Observed-Adverse-Effect-Levels (NOAELs) were considered to be 13000 p.p.m (mean achieved dosages of: 767 mg/kg/day in F0 males; 988, 881 or 2293 mg/kg/day in F0 females prior to mating, during gestation and during lactation, respectively; 1124 mg/kg/day in F1 males, and 1200, 912 or 2256 mg/kg/day in F1 females prior to mating, during gestation and during lactation, respectively).
Link to relevant study records
- Endpoint:
- two-generation reproductive toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Clinical signs:
- no effects observed
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- F0 generation: 3 deaths
- 1 female animal from control group, killed prematurely on Day 1 of lactation due to clinical signs (piloerection, subdued behaviour, pale eyes and skin, on Day 0 of lactation, some pups in the animals litter were found dead or had poor condition), cause of deteriotating condition was considered to be severe necrosis of the kidney.
- 1 male animal from mid dose group, killed prematurely on Day 99 due to clinical signs (shallow respiration, swelling of ventral abdomen, partially closed eyes), the demise of the animal was malignant lymophoma in mutliple tissues, considered to be an incidental finding, since no similar findings were noted in any other animals.
- 1 male animal in high dose group, killed prematurley due to a damaged right eye. Phthisis bulbi was considered to be the cause of the animal's condition, considered as an incidental finding, unrelated to test substance treatment. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- In F0 females in the high dose group mean body weights were lower than control from Day 8, continuing until pairing for mating and throughout gestation and lactation (ca. 5-7%). Reduced weight gain during pre-mating period (Days 1-71, ca. 11%, p<0.01), however no obvious reduction in gain noted over the gestation of lactation periods.
In F0 males slightly lower mean weight in the high dose group (1-4% compared to control) throughout the study, effect was too small to be positively attributed to test substance treatment and therefore considered not to be toxicologically relevant.
Group mean body weights and weight gains of mid and low dose group animals were comparable to controls. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Females: at highest dose mean food consumption 10-12% lower than control from Day 8, continuing until pairing for mating and throughout gestation and lactation. Group mean food consumption comparable to controls at mid and low dose groups.
Males: group mean food consumption generally similar between all groups throughout the study. At highest dose statistically lower consumption values were noted sporadically, however, the differences from control (around 2-3g) reflected pretrial differences between the groups, therefore the changes were not positively attributed to treatment. - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In the kidneys, test item-related findings included: higher incidences and severity of basophilic tubules in males at mid and high dose groups and females at high dose group; higher incidences and severity of hyaline droplets and hyaline casts in males at all dose levels and higher incidences mononuclear cell infiltration in males at high dose group. In females, the incidences of hyaline casts and mononuclear cell infiltration did not follow dose related patterns, and were therefore not positively attributed to treatment.
In the liver, a higher incidence of centrilobular hepatocellular hypertrophy was noted in both sexes at mid and high dose groups.
For details see table #6 below in section "Any other information on results incl. tables" - Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Motility was lower than controls in all treated groups, however, there was no dose-related pattern to the changes, therefore, they were judgded to be not positively attributed to treatment.
- Reproductive performance:
- effects observed, treatment-related
- Description (incidence and severity):
- No effects observed in mating performance, fertility and duration of gestation.
Litter size and pup mortality: at high dose group, mean numbers of implantation sites, total live pups born and number of live pups on Days 1-14 of lactation up to approx. 11% lower than controls; litter size comparable to controls at low and mid dose groups; pup survival was comparable to controls at all dose levels (slight inter-group differences considered to be too small to be attributed to treatment, additionally no obvious patterns or trends in the number of pups born alive and the number of pups born dead on Day 0 of lactation observed. For details see table #7 in section “Any other information on results incl. tables”. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 13 000 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: adaptive liver and kidney weight changes not considered to be relevant to humans
- Remarks on result:
- other: mean measured dosages: males: 767 mg/kg/day females: 988 mg/kg/day (prior to mating), 881 mg/kg/day (during gestation) or 2293 mg/kg/day (during lactation)
- Clinical signs:
- no effects observed
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- 2 male animals found dead in control group: 1 on Day 89, at necropsy epididymis was enlarged, there was no histopathological correlate, no other histopathological findings, evaluation of some tissues was not possible due to autolysis, cause of death undetermined. The second animal found dead on Day 54, no histopathological findings, evaluation of some tissues not possible due to autolysis, cause of death undetermined.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Group mean body weights were similar in all treated male groups throughout the study and all treated female groups prior to mating.
In high dose group females, mean body weights were lower than controls throughout gestation (up to approximately 8% on Day 20 of gestation) and there was a lower mean weight gain over Days 0-20 of gestation when compared with controls (approximately 17%).
Group mean body weights during gestation were comparable to controls at mid and low dose group animals. During lactation, female group mean body weights were similar in all groups. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Females: at high dose group, mean food consumption was approx. 5-10% lower than controls from Day 29 until pairing for mating (Day 72) and throughout gestation and lactation.
Males: group mean food consumption comparable to controls throughout the study in all dose levels. - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Higher kidney weights in males at mid and high dose groups (up to approximately 15% at high dose group), thyroid weights in males at high dose group (approximately 14-17%) and higher liver weights in both sexes at mid and high dose groups (up to approximately 14% in males and 32% in females) were noted, see table #8 below in section "Any other information on results incl. tables"
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In the kidneys of males, higher incidences and severity of hyaline droplets at all dose groups, basophilic tubules and mononuclear cell infiltration at mid and high dose groups and hyaline casts at high dose group were noted when compared with controls. In females, incidences of findings noted were generally similar in controls and treated groups; therefore the findings were not positively attributed to treatment.
In the liver, centrilobular hepatocellular hypertrophy was noted in both sexes at mid and high dose groups.
For details see table #9 below. - Details on results:
- In adult F1 females, reduced body weight gain during gestation for F1 animals correlated with lower mean food consumption throughout the majority of the study at the high dose group. In addition at the high dose group, a lower number of implantation sites and lower litter size, with correlating lower litter weight, were also noted in F1 females. It was considered that the litter findings were likely secondary to the maternal toxicity, and since there was no change in male or female pup weight or pup survival, these changes were considered not to be adverse. Oestrous cycles, mating performance, fertility, duration of gestation, pup weight, pup survival and maternal care were similar between all groups. There were also no obvious differences in these parameters between generations.
In F1 adults, higher kidney weights in males (mid and high dose group) correlated with histopathology findings of increased incidences and severity of hyaline droplets at all dose groups, basophilic tubules at mid and high dose groups, hyaline casts (at high dose group) and mononuclear cell infiltration (mid and high dose group), and there was a higher incidences of basophilic tubules in female kidneys at the high dose group. These findings were considered not to be adverse as they are considered adaptive responses to the administration of test materials and/or are species specific and are, therefore, not relevant to man.
In F1 adults, higher liver weights in both sexes at mid and high dose group correlated with an increased incidence of centrilobular hepatocellular hypertrophy. In studies where dosing periods are greater than 3 months, higher liver weights with correlating hypertrophy are considered not to be adverse if there was an absence of hepatotoxicity findings such as gross liver enlargement, evidence of hepatocyte necrosis, fibrosis or inflammation, evidence of degradation or necrosis of other liver cell types, and/or carcinogenicity. Since those types of changes were not present in this study, the higher weight and hypertrophy noted on this study were, therefore, considered to be non-adverse.
Higher thyroid weight in F1 males at the high dose group were considered not to be adverse since the findings were mild in nature and there were no histopathology correlates or any effects on reproduction which may indicate hormonal effects. - Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- effects observed, treatment-related
- Description (incidence and severity):
- Mating performance, fertility and duration of gestation: no effects observed.
Ovary scoring: in the high dose group, total number of ovarian follicles attributable to the number of single layer follicles approximately 30% lower than control. For details see table #10 below in section "Any other information on results incl. tables"
Mean numbers of implantation sites, total live pups born and number of live pups throughout lactation: at the highest dose level lower than controls (up to approximately 15%).
Litter size was comparable to controls at low and mid dose groups, pup survival comparable to controls at all dose levels. Slight intergroup differences were considered to be too small to be attributed to treatment with the test item, additionally there were no obvious patterns of trends in the number of pups presumed born alive and the number of pups presumed born dead on Day 0 of lactation.
For details see table #11 below in section "Any other information on results incl. tables"
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 13 000 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: decrease number of ovarian follicles with no histopathology and effect on reproductive function
- Remarks on result:
- other: mean measured dosages: males: 1124 mg/kg/day females: 1200 mg/kg/day (prior to mating), 912 mg/jkg/day (during gestation) or 2256 mg/kg/day (during lactation)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- The type and distribution of observations amongst pups did not indicate any association with test substance treatment.
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- At the high dose group, mean numbers of implantation sites, total live pups born and number of live pups on Days 1-14 of lactation were lower than controls (up to approximately 11%). Litter size was comparable to controls at low and mid dose groups and pup survival was comparable to controls at all dose levels. Slight inter-group differences were considered to be too small to be attributed to treatment. In addition, there were no obvious patterns or trends in the number of pups presumed born alive and the number of pups presumed born dead on Day 0 of lactation.
For details see table #12 below in section "Any other information on results incl. tables" - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At the high dose group, lower mean litter weight was noted throughout lactation (up to approximately 12%), when compared with controls. Mean litter weight at low and mid dose groups and mean male and female pup weights at all dose levels, were similar to controls throughout lactation.
For details see table #13 below in section "Any other information on results incl. tables" - Sexual maturation:
- effects observed, treatment-related
- Description (incidence and severity):
- Age and body weight of animals at vaginal opening or preputial separation were slightly higher than controls at all dose levels, indicating a slight delay in sexual maturation.
For details see table #14 below in section "Any other information on results incl. tables" - Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No organ weight findings in F1 weanlings which were considered to be related to treatment.
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- ca. 13 000 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: mortality ahd body weight changes
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- The type and distribution of observations amongst pups did not indicate any association with test substance treatment.
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- At the high dose group, mean numbers of implantation sites, total live pups born and number of live pups throughout lactation were lower than controls (up to approximately 15%).
Litter size was comparable to controls at low and mid dose groups and pup survival was comparable to controls at all dose levels. Slight intergroup differences were considered to be too small to be attributed to treatment. In addition, there were no obvious patterns of trends in the number of pups presumed born alive and the number of pups presumed born dead on Day 0 of lactation.
For details see table #15 below in section "Any other information on results incl. tables" - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At the high dose group, lower mean litter weight was noted throughout lactation (up to approximately 16%), when compared with control.
Mean litter weight at low and mid dose groups and mean male and female pup weights at all dose levels, were similar to controls throughout lactation.
For details see table #16 below in section "Any other information on results incl. tables" - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- In males at mid and high dose groups, statistically significantly higher mean absolute and covariate brain weights (up to approximately 6% at the high dose group) were observed when compared to controls.
For details see table #17 below in section "Any other information on results incl. tables" - Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F2
- Effect level:
- ca. 13 000 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: slight brain weight changes in absence of histopathology
- Remarks on result:
- other:
- Remarks:
- not considered toxicologically significant
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- In conclusion, the dietary administration of Alcohols, C2-33, manuf. Of, by-products from, overheads (the scource substance) to rats was well tolerated, and the parental and reproductive No-Observed-Adverse-Effect-Levels (NOAELs) were considered to be 13000 p.p.m (mean achieved dosages of: 767 mg/kg/day in F0 males; 988, 881 or 2293 mg/kg/day in F0 females prior to mating, during gestation and during lactation, respectively; 1124 mg/kg/day in F1 males, and 1200, 912 or 2256 mg/kg/day in F1 females prior to mating, during gestation and during lactation, respectively). A No-Observed-Effect-Level (NOEL) could not be established due to the presence of non-adverse findings in the kidneys of males at all dose levels.
- Executive summary:
The study was designed to provide general information concerning the effects of the source substance, Alcohols, C2-33, manuf. of, by-products from, overheads (876065-86-0), on reproductive performance when given orally to rats.
F0 animals were randomised into three test groups and one control group. These animals were dosed for 10 weeks prior to mating, and then throughout mating, gestation and lactation until termination after their litters (F1) reached Day 21 of lactation.
From each group, 24 males and 24 females were retained for post weaning assessments. These F1 animals continued dosing for 10 weeks after weaning, and then throughout mating, gestation and lactation until termination after their litters (F2) reached Day 21 of lactation.
The study design was as follows:
Group Dose level
(mg/kg/day)
Dose level
(ppm)
Number of F0 animals Number of F1 animals Males Females Males Females control* 0 0 28 28 24 24 low dose 100 1500 28 28 24 24 mid dose 500 6500 28 28 24 24 high dose 1000 13000 28 28 24 24 * The control diet was untreated SDS VRF-1 ground diet.
Animals from both generations were monitored for clinical signs of toxicity and for effects on body weight, food consumption, oestrous cycle, mating performance, pregnancy performance, difficulty or prolongation of parturition and for deficiencies in maternal care. The offspring were monitored for survival and growth up to weaning. In addition, the following endpoints were evaluated in both generations: gross necropsy findings, organ weights, histopathological evaluation, qualitative examination of the testes and examination of the ovaries and sperm.
There were 5 unscheduled deaths during the course of the study, 3 adult F0 generation animals and 2 adult F1 generation animals. All deaths were considered to be incidental and unrelated to treatment with the test item.
There were no clinical observations in either generation which were considered to be related to treatment with the test item.
At 13000 ppm, reduced mean weight gain was noted in F0 adult females during the premating period (approximate 10%) and in F1 adult females during gestation (approximately 17%), when compared with controls. There were no effects on body weight in males of either generation at any dose level or in females of either generation at 1500 or 6500 ppm.
At 13000 ppm, lower mean food consumption was noted in adult F0 and F1 females throughout the majority of pre-mating, gestation and lactation period (up to approximately 12% or 10% in the F0 and F1 generations, respectively). There were no effects on food consumption in males of either generation at any dose level or in females of either generation at 1500 or 6500 ppm.
Oestrous cycles, mating performance, fertility, duration of gestation and maternal care were similar between all groups in both generations. There were also no obvious differences in these parameters between generations.
At 13000 ppm, lower numbers of implantation sites and lower litter size with correlating lower litter weight, were noted in both generations, when compared with Controls (approximately 11-12% or 15-16% for all parameters in the F1 and F2 litters, respectively). It was considered that these findings were likely secondary to the maternal body weight and food consumption changes. Mean number of implantations sites, litter size and litter weight were similar to controls of both generations at 1500 or 6500 ppm.
Mean pup weights (male and female) and mean pup survival were similar between all groups in both generations. There were also no obvious differences in these parameters between generations.
In F1 adults, a slight delay in sexual maturation, as indicated by slightly higher ages and weights at vaginal opening or preutial separation, was noted at all dose levels.
In F0 generation adults, pathology findings included: higher kidney weights in males at ≥1500 ppm, which correlated with histopathology findings of increased incidences and severity of hyaline droplets (≥1500 ppm), basophilic tubules (≥6500 ppm) and hyaline casts and mononuclear cell infiltration (males at 13000 ppm); higher incidences of basophilic tubules in female kidneys at 13000 ppm; higher liver weights in both sexes at ≥ 6500 ppm, which correlated with a slightly increased incidence of macroscopic prominent lobular architecture at 13000 ppm and centrilobular hepatocellular hypertrophy at ≥ 6500 ppm; and higher thyroid weights in males at ≥ 1500 ppm (no macroscopic or histopathology correlates).
In F1 generation adults, pathology findings included higher kidney weights in males at ≥ 6500 ppm, which correlated with histopathology findings of increased incidences and severity of hyaline droplets (≥1500 ppm) , basophilic tubules and mononuclear cell infiltration (≥6500 ppm) and hyaline casts (13000 ppm); and higher liver weights with correlating centrilobular hepatocellular hypertrophy in both sexes at ≥ 6500 ppm. In F0 females at 13000 ppm, the number and type of ovarian follicles was similar to controls. In F1 females at 13000 ppm, the total number ovarian follicles, attributed to the number of single layer follicles, was approximately 30% lower than controls.
There were no changes in the number of sperm or spermatids, sperm morphology or sperm motility in males of either generation which were considered to be related to treatment with the test item.
There were no toxicologically relevant organ weight, gross necropsy or histopathology findings in the weanlings of either generation (F1 pups or F2 pups) which were considered to be related to treatment with the test item.
None of the aforementioned changes were considered to be adverse, but were considered to be either adaptive or not relevant to man..
In conclusion, the dietary administration of Alcohols, C2-33, manuf. Of, by-products from, overheads (876065-86-0) to rats was well tolerated, and the parental and reproductive No- Observed-Adverse-Effect-Levels (NOAELs) were considered to be 13000 ppm (mean achieved dosages of: 767 mg/kg/day in F0 males and 988, 881 and 2293 mg/kg/day in F0 females prior to mating, during gestation and during lactation, respectively; and 1124 mg/kg/day in F1 males and 1200, 912 and 2256 mg/kg/day in F1 females prior to mating, during gestation and during lactation, respectively). A No-Observed-Effect-Level (NOEL) could not be established due to the presence of non-adverse findings in the kidneys of males at all dose levels.
Reference
Higher kidney weights in males correlated with histopathology findings of increased incidences and severity of hyaline droplets (all dose groups) , basophilic tubules (mid and high dose groups), hyaline casts and mononuclear cell infiltration (high dose group), and there was a higher incidence of basophilic tubules in female kidneys in the high dose group animals. These findings were considered not to be adverse as they are considered adaptive responses to the administration of test materials and/or are species specific and are, therefore, not relevant to man.
In both sexes, higher liver weights at mid and high dose groups correlated with an increased incidence of centrilobular hepatocellular hypertrophy. A slightly increased incidence of prominent lobular architecture was noted macroscopically in males at the highest dose level (7 animals compared with 3 control animals), however, this did not always correlate with the histopathology findings, therefore, the macroscopic finding was not positively attributed to treatment with the test item. In studies where dosing periods are greater than 3 months, higher liver weights with correlating hypertrophy are considered not to be adverse if there was an absence of hepatotoxicity findings such as gross liver enlargement, evidence of hepatocyte necrosis, fibrosis or inflammation, evidence of degradation or necrosis of other liver cell types, and/or carcinogenicity. Since those types of changes were not present in this study, the higher weight and hypertrophy noted on this study were, therefore, considered to be non-adverse.
Higher thyroid weight in males at all dose groups were considered not to be adverse since the findings were mild in nature and there were no histopathology correlates or any effects on reproduction which may indicate hormonal effects.
Table #2: Summary of formulation analysis results | |||||
Timepoint | Dose group | Theoretical concentration (ppm) | mean found concentration (ppm) | RSD | % Difference from theoretical concentration |
Week 1 | control | 0 | 0 | - | - |
low dose | 1500 | 1323 | 1.0 | -11.8 | |
mid dose | 6500 | 5575 | 5.7 | -14.2 | |
high dose | 13000 | 11145 | 5.8 | -14.3 | |
Week 5 | control | 0 | 0 | - | - |
low dose | 1500 | 1342 | 1.9 | -10.5 | |
mid dose | 6500 | 6321 | 3.5 | -2.8 | |
high dose | 13000 | 12002 | 2.7 | -7.7 | |
Week 10 | control | 0 | 0 | - | - |
low dose | 1500 | 1374 | 5.0 | -8.4 | |
mid dose | 6500 | 5670 | 2.9 | -12.4 | |
high dose | 13000 | 12241 | 9.3 | -5.8 | |
Week 15 | control | 0 | 0 | - | - |
low dose | 1500 | 1315 | 3.9 | -12.3 | |
mid dose | 6500 | 5899 | 1.2 | -9.4 | |
high dose | 13000 | 11696 | 3.3 | -10.0 | |
Week 20 | control | 0 | 0 | - | - |
low dose | 1500 | 1440 | 3.7 | -4.0 | |
mid dose | 6500 | 5586 | 0.7 | -14.1 | |
high dose | 13000 | 1191 | 2.2 | -7.8 | |
Acceptance criteria | ≤10% | -15 to +5% | |||
Table #3: Summary of achieved dose levels | ||||||||
Group / sex | low dose / M | mid dose / M | high dose / M | low dose / F | mid dose / F | high dose / F | ||
Treatment level (ppm) | 1500 | 6500 | 13000 | 1500 | 6500 | 13000 | ||
Target dose level (mg/kg/d) | 100 | 500 | 1000 | 100 | 500 | 1000 | ||
Actual group mean dose level (mg/kg/d) | F0 | 90 | 385 | 767 | Prior to mating | 122 | 510 | 988 |
Gestation | 102 | 443 | 881 | |||||
Lactation* | 279 | 1173 | 2293 | |||||
F1 | 128 | 551 | 1124 | Prior to mating | 141 | 640 | 1200 | |
Gestation | 106 | 440 | 912 | |||||
Lactation* | 276 | 1113 | 2256 | |||||
*Results during lactation should be treated with caution as consumption is known to be variable during this time and there is a large amount of scatter and/or diet eaten by pups. | ||||||||
Table #4: Summary of test item-related organ weight findings - F0 adults | ||||||||
Males | Females | |||||||
Group | control | low dose | mid dose | high dose | control | low dose | mid dose | high dose |
Dose (ppm) | 0 | 1500 | 6500 | 13000 | 0 | 1500 | 6500 | 13000 |
No. animals per group | 28 | 28 | 27 | 27 | 27 | 28 | 28 | 28 |
Kidney | ||||||||
Absolute value (g) | 3.69 | 4.00* | 4.11*** | 4.29*** | 2.36 | 2.39 | 2.43 | 2.40 |
Absolute (covariance analysis) | 3.70 | 3.89* | 4.09*** | 4.41*** | 2.35 | 2.37 | 2.43 | 2.42 |
% of body weight | 0.655 | 0.687* | 0.722*** | 0.784*** | 0.740 | 0.745 | 0.768 | 0.766 |
Liver | ||||||||
Absolute value (g) | 19.50 | 20.65 | 20.86* | 22.23*** | 15.65 | 16.42 | 18.01*** | 20.36*** |
Absolute (covariance analysis) | 19.59 | 20.00 | 20.74** | 22.93*** | 15.62 | 16.24 | 18.02*** | 20.57*** |
% of body weight | 3458 | 3.578 | 3.665** | 4.054*** | 4.903 | 5.110 | 5.686*** | 6.489*** |
Thyroid gland | ||||||||
Absolute value (g) | 0.0233 | 0.0266* | 0.265* | 0.0271** | 0.0188 | 0.0212 | 0.0190 | 0.0201 |
Absolute (covariance analysis) | 0.0246 | 0.266* | 0.265* | 0.0271** | 0.0188 | 0.0211 | 0.190 | 0.0201 |
% of body weight | 0.00415 | 0.00463* | 0.00471* | 0.00492** | 0.00595 | 0.00666 | 0.00600 | 0.00644 |
Terminal body weight used as covariance | ||||||||
Significantly different from control group value: * = p<0.05, ** = p<0.01, *** = p<0.001 | ||||||||
Table #5: Summary test item-related necropsy findings - F0 adults | ||||||||
Males | Females | |||||||
Group | Control | Low dose | Mid dose | High dose | Control | Low dose | Mid dose | High dose |
Dose (ppm) | 0 | 1500 | 6500 | 13000 | 0 | 1500 | 6500 | 13000 |
No. Animals examined | 28 | 28 | 27 | 27 | 27 | 28 | 28 | 28 |
Liver prominent lobular architecture | 3 | 4 | 4 | 7 | 0 | 1 | 0 | 0 |
Table #6: Summary of test item related histopathology findings - F0 adults | ||||||||
Males | Females | |||||||
Group | control | low dose | mid dose | high dose | control | low dose | mid dose | high dose |
Dose (ppm) | 0 | 1500 | 6500 | 13000 | 0 | 1500 | 6500 | 13000 |
No. of animals examined | 28 | 28 | 27 | 27 | 27 | 28 | 28 | 28 |
Kidney (No. examined) | (28) | (28) | (27) | (27) | (27) | (28) | (27) | (28) |
Hyaline droplets, tubular | 5 | 19 | 27 | 27 | 0 | 0 | 0 | 0 |
Minimal | 5 | 17 | 6 | 3 | 0 | 0 | 0 | 0 |
Mild | 0 | 2 | 21 | 20 | 0 | 0 | 0 | 0 |
Moderate | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
Hyaline casts | 5 | 7 | 6 | 18 | 1 | 4 | 1 | 4 |
Minimal | 5 | 7 | 6 | 14 | 1 | 4 | 1 | 4 |
Mild | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
Basophilic tubules, focal | 17 | 17 | 20 | 24 | 3 | 4 | 6 | 10 |
Minimal | 17 | 17 | 18 | 6 | 3 | 4 | 6 | 7 |
Mild | 0 | 0 | 2 | 15 | 0 | 0 | 0 | 3 |
Moderate | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
Mononuclear cell infiltration | 14 | 13 | 15 | 20 | 4 | 5 | 6 | 6 |
Minimal | 14 | 13 | 15 | 17 | 4 | 4 | 6 | 6 |
Mild | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 |
Liver (No. examined) | (28) | (28) | (27) | (27) | (27) | (28) | (28) | (28) |
Centrilobular hypertrophy, hepatocellular | 0 | 0 | 3 | 12 | 0 | 0 | 2 | 13 |
Minimal | 0 | 0 | 3 | 10 | 0 | 0 | 2 | 10 |
Mild | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
Table #7: Duration of gestation and overall litter performance: F0 generation, F1 production | ||||||
Group | Control | Low dose | Mid dose | High dose | ||
Dose (ppm) | 0 | 1500 | 6500 | 13000 | ||
Number pregnant | 26 | 27 | 27 | 28 | ||
Duration of gestation (days): | ||||||
21 | 8 | 6 | 9 | 9 | ||
22 | 18 | 21 | 18 | 17 | ||
Mean duration | 21.7 | 21.8 | 21.7 | 21.7** | ||
Number females producing a live litter | 26 | 27 | 27 | 28 | ||
Gestation index (%) | 100 | 100 | 100 | 100 | ||
Mean number of implant sites* per pregnancy ± SD | 15.4 ± 1.9 | 15.4 ± 2.8 | 15.5 ± 2.8 | 13.8 ± 2.0 | ||
Mean total number of pups* born per litter | 14.5 ± 2.6 | 14.3 ± 2.6 | 14.3 ± 2.6 | 12.9 ± 1.8 | ||
Mean number of live pups* per litter ± SD: | ||||||
Day 0 of lactation | 14.2 ± 2.6 | 14.2 ± 2.6 | 14.3 ± 2.6 | 12.8 ± 1.8 | ||
Day 1 of lactation | 14.0 ± 2.6 | 14.1 ± 2.6 | 14.3 ± 2.6 | 12.6 ± 1.8 | ||
Day 4 of lactation | 13.1 ± 3.7 | 14.0 ± 2.8 | 14.1 ± 2.4 | 12.4 ± 2.1 | ||
Day 7 of lactation | 13.0 ± 3.7 | 13.9 ± 2.8 | 13.9 ± 2.3 | 12.3 ± 2.2 | ||
Day 14 of lactation | 12.2 ± 3.7 | 13.0 ± 3.0 | 12.7 ± 3.2 | 11.4 ± 2.5 | ||
Day 21 of lactation | 11.7 ± 3.7 | 12.5 ± 3.4 | 12.1 ± 3.5 | 11.3 ± 2.9 | ||
Total number of males* on Day 1 of lactation (%) | 188 (54) | 185 (49) | 173 (45) | 174 (49) | ||
Total number of females* on Day 1 of lactation (%) | 161 (46) | 196 (51) | 213 (55) | 180 (51) | ||
*= animals rearing young to Day 21 of lactation only | ||||||
** = excludes two animals where gestation lenght not calculable due to no positive mating sign being noted | ||||||
Table #8: Summary of test item-related organ weight findings - F1 adults | ||||||||
Males | Females | |||||||
Group | control | low dose | mid dose | high dose | control | low dose | mid dose | high dose |
Dose (ppm) | 0 | 1500 | 6500 | 13000 | 0 | 1500 | 6500 | 13000 |
No. animals per group | 22 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Kidney | ||||||||
Absolute value (g) | 3.80 | 3.92 | 4.31*** | 4.35*** | 2.45 | 2.54 | 2.57 | 2.53 |
Absolute (covariance analysis) | 3.79 | 3.89 | 4.26*** | 4.44*** | 2.45 | 2.52 | 2.56 | 2.56 |
% of body weight | 0.687 | 0.706 | 0.770*** | 0.812*** | 0.752 | 0.770 | 0.787 | 0.787 |
Liver | ||||||||
Absolute value (g) | 19.44 | 20.13 | 21.70** | 21.30* | 15.46 | 16.60 | 18.02*** | 20.17*** |
Absolute (covariance analysis) | 19.37 | 19.94 | 21.39*** | 21.87*** | 15.49 | 16.41 | 17.91*** | 20.43*** |
% of body weight | 3.508 | 3.614 | 3.865*** | 3.979*** | 4.754 | 5.022 | 5.497*** | 6.268*** |
Thyroid gland | ||||||||
Absolute value (g) | 0.0219 | 0.0234 | 0.0231 | 0.0248 | 0.0202 | 0.0234 | 0.0205 | 0.0206 |
Absolute (covariance analysis) | 0.0219 | 0.0233 | 0.229 | 0.0251** | 0.0202 | 0.0233 | 0.0205 | 0.0206 |
% of body weight | 0.00397 | 0.00422 | 0.00415 | 0.00465*** | 0.00620 | 0.00712 | 0.00629 | 0.0042 |
Terminal body weight used as covariance | ||||||||
Significantly different from control group value: * = p<0.05, ** = p<0.01, *** = p<0.001 | ||||||||
Table #9: Summary of test item related histopathology findings - F1 adults | ||||||||
Males | Females | |||||||
Group | control | low dose | mid dose | high dose | control | low dose | mid dose | high dose |
Dose (ppm) | 0 | 1500 | 6500 | 13000 | 0 | 1500 | 6500 | 13000 |
No. of animals examined | 22 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Kidney (No. examined) | (22) | (24) | (24) | (24) | (24) | (24) | (24) | (24) |
Hyaline droplets, tubular | 2 | 13 | 24 | 23 | 0 | 0 | 0 | 0 |
Minimal | 2 | 13 | 5 | 23 | 0 | 0 | 0 | 0 |
Mild | 0 | 0 | 19 | 17 | 0 | 0 | 0 | 0 |
Moderate | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
Hyaline casts | 5 | 5 | 5 | 18 | 2 | 3 | 0 | 4 |
Minimal | 5 | 5 | 5 | 15 | 2 | 3 | 0 | 4 |
Mild | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
Basophilic tubules, focal | 15 | 16 | 21 | 21 | 3 | 4 | 4 | 3 |
Minimal | 14 | 16 | 16 | 13 | 3 | 4 | 4 | 3 |
Mild | 1 | 0 | 5 | 6 | 0 | 0 | 0 | 0 |
Moderate | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
Mononuclear cell infiltration | 9 | 10 | 18 | 19 | 5 | 5 | 5 | 5 |
Minimal | 9 | 10 | 17 | 15 | 5 | 5 | 5 | 5 |
Mild | 0 | 0 | 1 | 4 | 0 | 0 | 0 | 0 |
Liver (No. examined) | (22) | (24) | (24) | (24) | (24) | (24) | (24) | (24) |
Centrilobular hypertrophy, hepatocellular | 0 | 0 | 4 | 8 | 0 | 0 | 2 | 9 |
Minimal | 0 | 0 | 4 | 6 | 0 | 0 | 2 | 8 |
Mild | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
Table #10: Ovary scoring: mean values ± standard deviation: F1 generation | |||
Follicles | Group/dose levels (ppm) | ||
control | high dose | ||
(0) | (13000) | ||
Single layer follicles | 22 ± 13 | 14 ± 9 | |
Multiple layer follicles | 3 ± 2 | 2 ± 2 | |
Antral follicles | 2 ± 2 | 2 ± 2 | |
Total follicles counted | 16 ± 15 | 18 ± 11 | |
Table #11: Duration of gestation and overall litter performance: F1 generation, F2 production | ||||||
Group | Control | Low dose | Mid dose | High dose | ||
Dose (ppm) | 0 | 1500 | 6500 | 13000 | ||
Number pregnant | 22 | 23 | 23 | 23 | ||
Duration of gestation (days): | ||||||
21 | 2 | 3 | 3 | 3 | ||
22 | 16 | 13 | 19 | 18 | ||
23 | 4 | 7 | 1 | 2 | ||
Mean duration | 22.1 | 22.2 | 21.9 | 22.0 | ||
Number females producing a live litter | 22 | 23 | 22 | 23 | ||
Gestation index (%) | 100 | 100 | 96 | 100 | ||
Mean number of implant sites* per pregnancy ± SD | 16.6 ± 2.3 | 16.3 ± 3.1 | 16.6 ± 2.4 | 14.7 ± 2.5 | ||
Mean total number of pups* born per litter | 15.5 ± 2.3 | 15.5 ± 3.1 | 14.7 ± 3.4 | 13.2 ± 2.5 | ||
Mean number of live pups* per litter ± SD: | ||||||
Day 0 of lactation | 15.2 ± 1.9 | 15.4 ± 3.1 | 14.6 ± 3.4 | 13.2 ± 2.5 | ||
Day 1 of lactation | 15.0 ± 2.0 | 14.8 ± 3.4 | 14.5 ± 3.4 | 12.9 ± 2.6 | ||
Day 4 of lactation | 14.8 ± 1.9 | 14.2 ± 3.3 | 14.3 ± 3.4 | 12.7 ± 2.6 | ||
Day 7 of lactation | 14.7 ± 1.8 | 14.0 ± 3.5 | 14.3 ± 3.4 | 12.7 ± 2.5 | ||
Day 14 of lactation | 14.7 ± 1.8 | 14.0 ± 3.5 | 14.2 ± 3.4 | 12.6 ± 2.5 | ||
Day 21 of lactation | 14.7 ± 1.8 | 14.0 ± 3.5 | 14.2 ± 3.4 | 12.6 ± 2.5 | ||
Total number of males* on Day 1 of lactation (%) | 142 (45) | 177 (52) | 159 (50) | 147 (52) | ||
Total number of females* on Day 1 of lactation (%) | 174 (55) | 164 (48) | 160 (50) | 136 (48) | ||
* = animals rearing young to Day 21 of lactation only | ||||||
Table #12: Survival indices: F0 generation, F1 production | |||||
Group | control | low dose | mid dose | high dose | |
Dose (ppm) | 0 | 1500 | 6500 | 13000 | |
Birth index | Mean litter index (%) | 94 | 94* | 93 | 93 |
Number losing >2 pups | 3 | 2 | 6 | 4 | |
Number of litters | 26 | 25* | 27 | 28 | |
Live birth index | Mean litter index (%) | 98 | 100 | 100 | 100 |
Number losing >1 pup | 1 | 0 | 0 | 0 | |
Number of litters | 26 | 27 | 27 | 28 | |
Viability index | Mean litter index (%) | 93 | 98 | 99 | 97 |
Days 0 - 4 | Number losing >3 pups | 1 | 0 | 1 | 1 |
Number of litters | 26 | 27 | 27 | 28 | |
Lactation index | Mean litter index (%) | 91 | 89 | 86 | 92 |
Days 4 - 21 | Number losing >1 pup | 5 | 8 | 10 | 6 |
Number of litters | 25 | 27 | 27 | 28 | |
Overall survival index | Mean litter index (%) | 84 | 88 | 85 | 88 |
Birth - 21 | Number losing >4 pups | 6 | 3 | 5 | 3 |
Number of litters | 26 | 27 | 27 | 28 | |
* = Litters where birth index not calculable excluded | |||||
Table #13: Group mean litter and pup weight: F0 generation, F1 production | ||||
Day of lactation | Group/dose level (ppm) | |||
control | low dose | mid dose | high dose | |
0 | 1500 | 6500 | 13000 | |
Litter | ||||
Day 1 | 93 ± 19 | 95 ± 15 | 98 ± 13 | 87 ± 12 |
Day 4 | 136 ± 21 | 138 ± 20 | 140 ± 18 | 123 ± 22 |
Day 7 | 200 ± 27 | 205 ± 30 | 201 ± 27 | 176 ± 31 |
Day 14 | 361 ± 48 | 376 ± 51 | 357 ± 64 | 322 ± 61 |
Day 21* | 587 ± 91 | 608 ± 77 | 579 ± 102 | 530 ± 75 |
Mean of litter mean pup weight | ||||
Males | ||||
Day 1 | 7.0 ± 0.9 | 7.0 ± 0.7 | 7.2 ± 0.7 | 7.1 0.6** |
Day 4 | 10.4 ± 1.5 | 10.4 ± 1.3 | 10.4 ± 1.4 | 10.2 1.3 |
Day 7 | 15.3 ± 2.2 | 15.5 ± 1.8 | 15.1 ± 2.0 | 14.8 2.0 |
Day 14 | 29.5 ± 4.5 | 30.4 ± 4.5 | 29.8 ± 3.9 | 28.9 3.5 |
Day 21 | 50.6 ± 9.5 | 49.2 ± 8.7 | 49.0 ± 8.5 | 47.1 6.4 |
Females | ||||
Day 1 | 6.4 ± 1.2 | 6.6 ± 0.7 | 6.7 ± 0.7 | 6.7 ± 0.7** |
Day 4 | 9.8 ± 1.4 | 9.8 ± 1.2 | 9.8 ± 1.3 | 9.7 ± 1.3 |
Day 7 | 14.7 ± 2.1 | 14.6 ± 1.9 | 14.4 ± 1.8 | 14.1 ± 2.0 |
Day 14 | 29.0 ± 4.6 | 29.5 ± 4.8 | 28.2 ± 3.8 | 28.1 3.6 |
Day 21 | 47.5 ± 7.7 | 47.7 ± 8.7 | 46.6 ± 7.4 | 45.2 5.9 |
Means exclude litters where all pups died. | ||||
* = excludes litters where not all pups weighed on Day 21 of lactation in error | ||||
** = excludes litter where pups mis-sexed on Day 1 of lactation | ||||
Table #14: Preputial separations and vaginal openings: F1 generation | ||||
Group/dose level (ppm) | ||||
control | low dose | mid dose | high dose | |
0 | 1500 | 6500 | 13000 | |
Females | ||||
Age (days) at vaginal openings | 33.0 ± 1.7 | 34.1 ± 1.7 | 34.8 ± 1.2 | 35.8 ± 2.4 |
Weight (g) at vaginal opening | 108 ± 12 | 117 ± 14 | 116 ± 12 | 119 ± 16 |
Males | ||||
Age (days) at preputial separation | 40.7 ± 1.3 | 41.0 ± 1.7 | 41.4 ± 1.5 | 42.4 ± 2.3 |
Weight (g) at preputial separation | 192 ± 21 | 194 ± 20 | 197 ± 19 | 201 ± 18 |
Table #15: Survival indices: F1 generation, F2 production |
|||||
Group | control | low dose | mid dose | high dose | |
Dose (ppm) | 0 | 1500 | 6500 | 13000 | |
Birth index | Mean litter index (%) | 94 | 95 | 88 | 90 |
Number losing >2 pups | 2 | 2 | 3 | 2 | |
Number of litters | 22 | 23 | 22 | 23 | |
Live birth index | Mean litter index (%) | 99 | 99 | 99 | 100 |
Number losing >1 pup | 1 | 0 | 1 | 0 | |
Number of litters | 22 | 23 | 23 | 23 | |
Viability index | Mean litter index (%) | 93 | 92 | 94 | 92 |
Days 0 - 4 | Number losing >3 pups | 2 | 2 | 2 | 1 |
Number of litters | 22 | 23 | 23 | 23 | |
Lactation index | Mean litter index (%) | 95 | 98 | 95 | 99 |
Days 4 - 21 | Number losing >1 pup | 1 | 1 | 0 | 0 |
Number of litters | 22 | 23 | 23 | 22 | |
Overall survival index | Mean litter index (%) | 91 | 91 | 93 | 91 |
Birth - 21 | Number losing >4 pups | 3 | 2 | 1 | 1 |
Number of litters | 22 | 23 | 23 | 23 | |
Table #16: Group mean litter and pup weight: F1 generation, F2 production | ||||
Day of lactation | Group/dose level (ppm) | |||
control | low dose | mid dose | high dose | |
0 | 1500 | 6500 | 13000 | |
Litter | ||||
Day 1* | 103 ± 12 | 100 ± 25 | 99 ± 23 | 90 ± 17 |
Day 4 | 150 ± 25 | 145 ± 37 | 147 ± 32 | 133 ± 24 |
Day 7 | 221 ± 34 | 212 ± 51 | 214 ± 43 | 194 ± 32 |
Day 14 | 415 ± 46 | 398 ± 78 | 388 ± 65 | 347 ± 49 |
Day 21 | 661 ± 74 | 652 ± 127 | 632 ± 108 | 575 ± 80 |
Mean of litter mean pup weight | ||||
Males | ||||
Day 1* | 7.1 ± 0.7 | 7.0 ± 0.8 | 7.1 ± 0.7 | 7.3 ± 0.9 |
Day 4 | 10.4 ± 1.6 | 14.4 ± 1.1 | 10.8 ± 1.4 | 11.0 ± 1.5 |
Day 7 | 15.5 ± 2.2 | 15.6 ± 1.6 | 15.9 ± 2.4 | 16.0 ± 2.0 |
Day 14 | 29.1 ± 2.8 | 29.7 ± 4.3 | 29.0 ± 5.3 | 28.8 ± 4.0 |
Day 21 | 46.6 ± 5.3 | 48.9 ± 7.8 | 47.4 ± 7.7 | 48.2 ± 8.3 |
Females | ||||
Day 1 | 6.7 ± 0.6 | 6.6 ± 0.7 | 6.7 ± 0.9* | 6.9 ± 0.8 |
Day 4 | 10.0 ± 1.3 | 10.0 ± 1.0 | 10.2 ± 1.5 | 10.3 ± 1.5 |
Day 7 | 14.8 ± 1.9 | 14.9 ± 1.4 | 14.9 ± 2.3 | 15.1 ± 2.1 |
Day 14 | 27.9 ± 2.9 | 28.8 ± 4.5 | 27.7 ± 4.7 | 27.4 ± 4.0 |
Day 21 | 44.6 ± 5.3 | 47.1 ± 6.8 | 44.7 ± 7.7 | 45.6 ± 7.6 |
Means exclude litters where all pups died. | ||||
* = excludes litters that were miscounted and/or mis-sexed on Day 1 of lactation | ||||
Table #17: Summary of test item-related organ weight findings - F2 Weanlings | ||||||||
Males | Females | |||||||
Group | control | low dose | mid dose | high dose | control | low dose | mid dose | high dose |
Dose (ppm) | 0 | 1500 | 6500 | 13000 | 0 | 1500 | 6500 | 13000 |
Brain | ||||||||
Absolute value (g) | 1.51 | 1.52 | 1.57* | 1.61*** | 1.46 | 1.48 | 1.51 | 1.51 |
Absolute (covariance analysis) | 1.51 | 1.52 | 1.56* | 1.60*** | 1.47 | 1.48 | 1.51 | 1.50 |
% of body weight | 2.853 | 2.854 | 2.807 | 2.837 | 2.884 | 2.925 | 2.938 | 2.936 |
Terminal body weight used as covariance | ||||||||
Significantly different from control group value: * = p<0.05, ** = p<0.01, *** = p<0.001 | ||||||||
Justification for classification or non-classification
In a preliminary, Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test (OECD 422) of the source substance, at a dose of 1000 mg/kg/day, there was an increase in the number of animals giving birth to dead pups and also in the number losing more than 3 pups over Days 0-4 of lactation, compared with Controls. Therefore, for the neonatal toxicity, the Lowest Observed Adverse Effect Level (LOAEL) was 1000 mg/kg/day and the No Observed Effect Level (NOEL) was considered to be 500 mg/kg/day.From the findings on this study, the parental NOAEL was considered to be 100 mg/kg/day, however, findings at 500 and 1000 mg/kg/day were confined to salivation, and kidney findings which may be reversible and not relevant in man. The neonatal NOEL was considered to be 500 mg/kg/day.As findings in this study were considered not to be relevant in man, the parental NOAEL for man could be 1000 mg/kg/day.
In a subsequent, two generation reproductive toxicity study (OECD 416), the dietary administration of the source substance was well tolerated, and the parental and reproductive No-Observed-Adverse-Effect-Levels (NOAELs) were considered to be 13000 p.p.m (mean achieved dosages of: 767 mg/kg/day in F0 males; 988, 881 or 2293 mg/kg/day in F0 females prior to mating, during gestation and during lactation, respectively; 1124 mg/kg/day in F1 males, and 1200, 912 or 2256 mg/kg/day in F1 females prior to mating, during gestation and during lactation, respectively).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.